Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024

LONDON, January 27, 2014 /PRNewswire/ --

New study shows you commercial prospects for leading eye drug producers

What does the future hold for top companies in the pharma ophthalmics industry? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 235 page report provides 152 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. We analyse the 38 leading companies for eye medicines, to help you see the future of that industry and market. You will see financial results, interviews, trends, opportunities, and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of five exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Professor David T. Shima, PhD, Institute of Ophthalmology, University College London
- Sean Ainsworth, CEO and Founder, RetroSense Therapeutics
- Philip G. Ralston, Jr., CEO, MacuCLEAR
- Dr. Michael Stewart, Associate Professor, Mayo Clinic
- Authority from a company in the industry (views provided anonymously)

Discover forecasts and discussions to help you stay ahead in knowledge

You will find revenue forecasts to 2024 for nine companies, 31 top drugs and the industry, with growth rates and market shares. Our investigation lets you assess the most lucrative areas of that industry, especially pharma companies at the forefront of treating eye disorders and diseases. We predict sales growth with many opportunities.

You can stay ahead in knowledge of the ophthalmic treatments market, benefiting your research and analyses. The following sections further highlight what you will find in our report.

See prospects for leading US manufacturers

Our report provides you with profiles and analyses for top companies based in the US:
•    Allergan
•    Merck
•    Pfizer
•    Regeneron

There you examine products, progress, results, R&D pipelines and companies' revenue potentials to 2024. Also, you find sales forecasts for brands such as Restasis, Lumigan, Eylea, Combigan and Cosopt.

You can assess strengths, weaknesses, opportunities and threats (SWOT factors). Also, you will find linked organisations, including alliances and licensing. Discover what the future holds. You see approvals and strategy too, and mergers and acquisitions (M&A activity).

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

What are the outlooks for leading European producers?

Our report shows you developments and prospects for leading European pharma manufacturers developing and producing medicines for optical disorders:
•    Novartis
•    Roche

You find outlooks to 2024, including revenue forecasting, as well as R&D and commercial drivers and restraints. Also, you discover sales forecasting for brands such as Lucentis, Avastin, Azopt, Vigamox and Jetrea. We show where sales growth can occur.

What are the prospects for companies based in the Asia-Pacific region?

You see outlooks for top companies developing and producing ocular drugs based in the Asia-Pacific region. Assess product portfolios, other activities and revenue predictions to 2024:
•    Santen
•    Senju
•    Valeant

You find sales prospects for brands such as Hyalein, Tapros/Taflotan, Cravit, and Diquas, along with R&D, strategies and driving and restraining forces from 2014 onwards.

Who are the leading emerging companies worldwide?

Our study also covers 29 other companies following after the world leaders. You discover activities of organisations including the following:
•    Abbott
•    Acucela
•    Aerie Pharmaceuticals
•    Aerpio Therapeutics
•    Akorn
•    Alimera Sciences
•    Altheos
•    Amakem
•    Ampio Pharmaceuticals
•    Bayer
•    BioDiem
•    Can-Fite BioPharma/OphthaliX
•    Chengdu Kanghong Pharmaceutical
•    Colby Pharmaceutical
•    Eleven Biotherapeutics
•    EyeGate Pharmaceuticals
•    Gene Signal
•    Icon Bioscience
•    Lpath
•    MacuCLEAR
•    Neurotech
•    Omeros
•    Ophthotech
•    Otsuka Pharmaceutical
•    OXiGENE
•    RXi Pharmaceuticals
•    Shire
•    Sirnaomics
•    ThromboGenics

You see outlooks for a wide range of companies, from multinationals to emerging specialists in the eye disorders field. Find developments for treating visual disorders and sight loss.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

You also find revenue predictions for the overall industry segment

Our report forecasts sales of ocular drugs by overall world market and product category. You see individual forecasted revenues and growth rates to 2024 for five world-level submarkets (therapeutic classes):
•    Glaucoma
•    Retinal disorders
•    Ophthalmic allergy, inflammation and infection
•    Dry eye
•    Other agents

We predict total ophthalmic drug revenues to reach $20.9bn in 2014. We forecast high growth there to 2024. Discover the sales potential of the world market and find its most promising segments.

How the Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024  report helps you

In summary, our 235 page report gives you the following knowledge:

• Profiles of 38 leading companies - discover product ranges, recent results, strategies and competition
• Outlooks for companies in eye medicine - assess top players worldwide, seeing opportunities, business data, challenges and commercial outlooks
• Forecasted ophthalmic drug revenues to 2024 for the top 9 companies - find predicted financial results for those medicines
• Predicted revenues of 31 leading drugs to 2024 - see potentials of top products
• Potential revenues to 2024 for the world ophthalmic drug market and 5 product categories (therapeutic classes) - find the industry's sales outlook
• Review of R&D pipelines - investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at            sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on http://www.visiongain.com/Report/1180/Drug-Discovery-Outsourcing-World-Market-Forecast-2014-2024

Companies Listed in this Report:

Abbott Laboratories (Abbott)
Abbvie
Acucela
Advanced Vision Research (acquired by Akorn)
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Pharmaceuticals
Alcon (subsidiary of Novartis)
Alimera Sciences
Allergan
Allergro Ophthalmics
Altheos
Amakem
Ampio Pharma
Asahi Glass
AstraZeneca
Aton Pharma (acquired by Valeant)
Banyu Pharmaceutical (part of Merck)
Bausch and Lomb (subsidiary of Valeant)
Bayer
Bayer Yakuhin (Japanese subsidiary of Bayer)
BioDiem
Biogen Idec
BioInvent International
Biovail Corporation (part of Valeant)
Bristol-Myers Squibb
Can-Fite BioPharma
Chengdu Kanghong Pharmaceutical
Chiron Corportation (part of Novartis)
Chugai Pharmaceutical (part of Roche)
CIBA VISION (part of Novartis)
Ciba-Geigy (part of Novartis)
Colby Pharmaceutical Company (Colby)
CoMentis
Daiichi Sankyo
Eleven Biotherapeutics
Eli Lilly and Company (Lilly)
EyeGate Pharmaceuticals
Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)
Fougera Pharmaceuticals (acquired by Novartis)
Gene Signal
Genentech (subsidiary of Roche)
Genzyme (subsidiary of Sanofi)
Gilead Sciences
GSK
ICN Pharmaceuticals (original Valeant company)
Icon Bioscience
Inamed Corporation (subsidiary of Allergan)
InSite Vision
Inspire Pharmaceuticals (acquired by Merck)
ISTA Pharmaceuticals (part of Valeant)
Jerini AG
Jerini Ophthalmic (part of Jerini AG)
Johnson & Johnson
Kestrel Ophthalmics
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
Lpath
MacuCLEAR
MacuSIGHT, Inc.
MAP Pharmaceuticals (acquired by Allergan)
Meda
Medicis Corporation (acquired by Valeant)
Merck & Co. (Merck)
MerLion Pharmaceuticals
MSD K.K. (part of Merck)
Mylan Pharmaceuticals
Mystic Pharmaceuticals
Neurotech
NicOx
Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)
NovaBay Pharmaceuticals
Novagali Pharma (acquired by Santen)
Novartis
Novo (subsidiary of Novo Nordisk)
Novo Nordisk
Oakwood Laboratories
OcuSciences
Omeros
Onyx Pharmaceuticals
OphthaliX (part-owned by Can-Fite BioPharma)
Ophthotech
OPKO Health
Ora
OSI Pharmaceuticals
Othera Pharmaceuticals (acquired by Colby)
Otsuka Pharmaceutical
Oxford BioMedica
OXiGENE
Parke-Davis (subsidiary of Pfizer)
PDL BioPharma
Pfizer
Pharmacia (acquired by Pfizer)
Potentia Pharmaceuticals
Premacure
Procter & Gamble
pSivida
Quark Pharmaceuticals
Reckitt Benckiser
Regeneron
RetroSense Therapeutics
ReVision Therapeutics
Roche
RXi Pharmaceuticals
Sandoz (part of Novartis)
Sanofi
Santen Pharmaceutical Co. (Santen)
SARcode Bioscience
Schering-Plough (part of Merck)
Senju
Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)
Senju USA Inc. (subsidiary of Senju)
Shire
Sirion Therapeutics
Sirna Therapeutics
Sirnaomics
SkinMedica (subsidiary of Allergan)
Spark Therapeutics
Symphony ViDA
Takeda Pharmaceutical
Teva
The Patent Board
ThromboGenics
Upjohn (acquired by Pfizer through Pharmacia)
Valeant Pharmaceuticals
Ventana Medical Systems (acquired by Roche)
Warburg Pincus LLC
Warner-Lambert (acquired by Pfizer)
Watson Pharmaceuticals
Wyeth Pharmaceuticals (part of Pfizer)

Other Organisations Mentioned in this Report

A*STAR Institute for Infocomm Research (Singapore)
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
Association for Research in Vision and Ophthalmology (ARVO)
Council of Europe
Emory University
European Medicines Agency (EMA)
Foundation Fighting Blindness (FFB) (US)
Health Canada
Institute of Experimental Medicine (Russia)
Institute of Ocular Pharmacology, Texas A&M (US)
Institute of Ophthalmology, University College London (UK)
Intellectual Property Appellate Board (India)
International Diabetes Federation
Internet Archive
Japan Patent Office (JPO)
Mayo Clinic
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Monash University
National Eye Institute (NEI) (US)
National Health Service (NHS) (UK)
National Institute for Health and Care Excellence (NICE) (UK)
NHS Scotland
Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)
Novartis Venture Funds (NVF) (part of Novartis)
Ophthalmology External Research Unit (part of Pfizer)
Ophthrisi (GSK research unit)
Rinat (Pfizer research unit)
Texas Emerging Technology Fund
Therapeutic Goods Administration (TGA) (Australia)
Tokyo University of Science
United States Food and Drug Administration (FDA)
University of Florida
University of Kentucky
University of Melbourne
University of Michigan
US Preventive Services Task Force (USPSTF)
US Securities and Exchange Commission (SEC)
World Health Organization (WHO)

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

SOURCE Visiongain